(19)
(11) EP 1 753 746 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.02.2012 Bulletin 2012/07

(45) Mention of the grant of the patent:
27.07.2011 Bulletin 2011/30

(21) Application number: 05747406.6

(22) Date of filing: 27.04.2005
(51) International Patent Classification (IPC): 
C07D 403/10(2006.01)
A61P 9/12(2006.01)
 A61K 31/41(2006.01)
(86) International application number:
PCT/EP2005/051911
(87) International publication number:
WO 2005/105789 (10.11.2005 Gazette 2005/45)

(54)

NOVEL PYRROLE DERIVATIVES WITH ANGIOTENSIN II ANTAGONIST ACTIVITY

NEUE PYRROLDERIVATE MIT ANGIOTENSIN-II-ANTAGONISTISCHER WIRKUNG

DERIVES DE PYRROLE POSSEDANT UNE ACTIVITE ANTAGONISTE DE L'ANGIOTENSINE II

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

(30) Priority: 28.04.2004 IT TO20040264

(43) Date of publication of application:
21.02.2007 Bulletin 2007/08

(73) Proprietor: ROTTAPHARM S.P.A.
20122 Milano (MI) (IT)

(72) Inventors:
  • MAKOVEC, Francesco
    I-20050 LESMO (Milano) (IT)
  • ARTUSI, Roberto
    I-20017 RHO (Milano) (IT)
  • GIORDANI, Antonio
    I-27100 PAVIA (IT)
  • ZANZOLA, Simona
    I-20132 MILANO (IT)
  • ROVATI, Lucio Claudio
    I-20052 MONZA (Monza-Brianza) (IT)

(74) Representative: Rambelli, Paolo et al
Jacobacci & Partners S.p.A. Corso Emilia 8
10152 Torino
10152 Torino (IT)


(56) References cited: : 
EP-A- 0 253 310
 EP-A- 0 323 841
   
  • PRASUN K CHAKRAVARTY: "ANTIHYPERTENSIVE AGENTS" EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 5, no. 5, 1 May 1995 (1995-05-01), pages 431-458, XP000567227 ISSN: 1354-3776 cited in the application
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).